Document is current
Any future updates will be listed below
-
Authors
Zhang, Chi https://orcid.org/0000-0002-9188-6307
Lu, Yu-jing https://orcid.org/0000-0003-2494-843X
Chen, Bingjie https://orcid.org/0000-0001-7689-2146
Bai, Zhiyan
Zeng, Qiaoxi
Hervieu, Alexia https://orcid.org/0000-0002-8061-6678
Licciardello, Marco P.
Mitsopoulos, Konstantinos
Al-Lazikani, Bissan
Tortorici, Marcello
Rossanese, Olivia W. https://orcid.org/0000-0002-1262-9522
Workman, Paul https://orcid.org/0000-0003-1659-3034
Clarke, Paul A. https://orcid.org/0000-0001-9342-1290
-
Funding
Funding for this research was provided by:
Cancer Research UK (C309/A11566)
Cancer Research UK (C2739/A22897)
Wellcome Trust (212969/Z/18/Z)
Wellcome Trust (094885/Z/10/Z)
- License Information
-
More Information
Article History
Received: 20 March 2025
Accepted: 5 February 2026
First Online: 18 February 2026
Competing interests
: C.Z., A.H., M.P.L., O.W.R., P.A.C., K.M., M.T., and P.W. are current or past employees of The Institute of Cancer Research, which has a commercial interest in a range of drug targets and operates a Rewards to Discoverers scheme, including A3B inhibitors, through which employees may receive financial benefits following the commercial licensing of a project. P.W. is an independent director at Storm Therapeutics, is a consultant/advisory board member at Astex Pharmaceuticals, CV6 Therapeutics, Black Diamond Therapeutics, Vividion Therapeutics and Nextechinvest; reports receiving a commercial research grant from Sixth Element Capital, Astex Pharmaceuticals, and Merck; has ownership interest in Storm Therapeutics, Chroma Therapeutics, and Nextechinvest; and has an unpaid consultant/advisory board relationship with the Chemical Probes Portal. The remaining authors declare no competing interests.
